BioCryst Pharma (BCRX) Offers Positive Results from BCX4430 PoC Study in Ebola Virus
Tweet Send to a Friend
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced positive results from a proof-of-concept study of its broad spectrum antiviral, BCX4430, for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
